Trial Profile
A trial to assess the effects of tiotropium bromide delivered via Handihaler or via Respimat in patients with COPD and chronic kidney disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2014
Price :
$35
*
At a glance
- Drugs Tiotropium bromide (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- 17 Sep 2014 New trial record